A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacyand Safety of VX-121Combination Therapy in Subjects With Cystic FibrosisWho Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)

Project: Research project

Project Details

Description

A Phase 3, Randomized, Double-blind, Controlled Study Evaluating the Efficacy and Safety of VX-121Combination Therapy in Subjects With Cystic Fibrosis Who Are Heterozygous for F508del and a Minimal Function Mutation (F/MF)
StatusActive
Effective start/end date9/1/21 → 9/1/23

Funding

  • Vertex Pharmaceuticals Incorporated

Fingerprint

Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
View full fingerprint